NRX Pharma Advances Ketamine Therapy Amid Major Mental Health Policy Shift

NRX Pharmaceuticals (NASDAQ: NRXP) is gaining momentum following a major U.S. policy shift supporting accelerated approval pathways for treatments targeting severe mental illness, including ketamine-based therapies. CEO Dr. Jonathan Javitt says the company’s preservative-free ketamine program is currently under FDA review, with a potential decision expected this summer.

The company is also expanding its Hope Therapeutics clinic network, combining ketamine treatment with technologies such as transcranial magnetic stimulation (TMS) and hyperbaric oxygen therapy to address severe depression, PTSD, and suicidal ideation. NRX believes growing regulatory support and real-world evidence could accelerate access to next-generation neuroplastic therapies.

#NRXPharma
#NRXP
#MentalHealth
#Ketamine
#Depression
#PTSD
#Psychedelics
#HealthcareInnovation
#Biotech
#ClinicalTrials
#FDA
#Neuroscience
#TMS
#MonicaMalpass
#NewsOut